Xeris Biopharma Holdings, Inc. (XERS)
$10.48+2.85%Close
BUYBULL · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.8B
- Beta
- 0.84
- P/E (TTM)
- -103.71
- Short % float
- 4.37%
- Days to cover
- 1.7
- SI change
- -10.6%
- 1W
- +15.42%
- 1M
- +36.64%
- vs SPY 1W
- +14.26%
- vs SPY 1M
- +33.64%
Industry peers
FMP comparable companies · ranked by market cap
- ASNDSELLAscendis Pharma A/S$13.8BRECOVERYQ 35$222.69+2.94%
- CORTBUYCorcept Therapeutics Incorporated$12.8BRECOVERYQ 22$118.54+2.24%
- MBXSELLMBX Biosciences, Inc. Common Stock$2.5BCRISISQ 38$53.25-0.02%
- SEPNSELLSepterna Inc$1.7BRECOVERYQ 28$36.90+3.98%
- ETONSELLEton Pharmaceuticals, Inc.$1.5BRECOVERYQ 33$54.75+0.84%
- GHRSSELLGH Research PLC$1.4BCRISISQ 16$20.45+3.23%
- MNKDSELLMannKind Corporation$1.1BCRISISQ 4$3.42-3.80%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on XERS?
- LOPJLB’s latest quantitative signal on Xeris Biopharma Holdings, Inc. (XERS) is BUY in a BULL regime. Signals are updated daily.
- What market regime is XERS in?
- Xeris Biopharma Holdings, Inc. (XERS) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Xeris Biopharma Holdings, Inc. (XERS) do?
- Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypok…